The Evolving Role of Orexin-Based Therapy in Narcolepsy Type 1 Management

This CE activity was designed to improve learners’ knowledge and competence in relation to the management of patients with NT1.

Credit Expired

0.75 CE Credit(s)

Expires: December 1, 2022

This activity is intended for neurology and primary care clinicians involved in the treatment of narcolepsy type 1 (NT1).

Upon successful completion of this educational activity, participants should be better able to:

Recognize contemporary challenges in the management of narcolepsy type 1 (NT1)
Evaluate the role of orexin in the underlying pathophysiology of NT1
Analyze available data on emerging orexin-based therapies for the treatment of NT1
Identify patients with NT1 who might derive benefit from treatment with orexin-based therapy

Professor, Neurology
Albert Einstein College of Medicine
Bronx, New York, United States

Professor, Neurology and Physiology
Sleep Unit, Gui de Chauliac Hospital
University of Montpellier
Montpellier, France

Professor, Neurology
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston Children’s Hospital
Boston, Massachusetts, United States

Featured RMEI CE Activities

Subscribe